ImmuPharma plc (LON:IMM – Get Free Report) traded up 42.2% during trading on Monday . The company traded as high as GBX 5.60 ($0.07) and last traded at GBX 5.60 ($0.07). 25,452,426 shares were traded during trading, an increase of 27% from the average session volume of 20,003,797 shares. The stock had previously closed at GBX 3.94 ($0.05).
ImmuPharma Price Performance
The stock’s fifty day moving average is GBX 1.92 and its 200-day moving average is GBX 1.78. The stock has a market capitalization of £19.57 million, a PE ratio of -470.00 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- Want to Profit on the Downtrend? Downtrends, Explained.
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Where Do I Find 52-Week Highs and Lows?
- What Does the Future Hold for Eli Lilly?
- Stock Dividend Cuts Happen Are You Ready?
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
